Following the strategic restructuring, Allakos reported that Lirentelimab failed in its Phase II studies for atopic dermatitis and chronic spontaneous urticaria. Read more.
Operator: Hello, and welcome to the AIM ImmunoTech Inaugural Fiscal Year 2022 Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.
Operator: Good day and thank you for standing by. Welcome to the Silence Therapeutics 2022 Annual Results Conference Call and Webcast. Please be advised that today s conference is being recorded.